A Phase I Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Adult Subjects With Relapsed/Refractory CD19+ B Cells Acute Lymphoblastic Leukemia(CALL-1)

Trial Profile

A Phase I Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Adult Subjects With Relapsed/Refractory CD19+ B Cells Acute Lymphoblastic Leukemia(CALL-1)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Acronyms CALL-1
  • Sponsors Cellular Biomedicine Group
  • Most Recent Events

    • 08 Aug 2017 According to a Cellular Biomedicine Group media release, top-line data from the study is expected by year-end.
    • 11 Jan 2017 New trial record
    • 10 Jan 2017 Planned End Date changed from 1 Jul 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top